SAN ANTONIO--(BUSINESS WIRE)--OncoVista Innovative Therapies, Inc. (OTCBB:OVIT) reported that it has initiated an additional safety study of OVI-117 in a 2nd animal species. “OncoVista is moving ahead in our development efforts,” said Alexander L. Weis, Ph.D., CEO of OncoVista. “We are advancing the development of OVI-117, our L-Nucleoside conjugate for solid tumors. This additional safety study is an important step in our efforts to bring this drug candidate into clinical trials.”
